MX344786B - Composiciones y metodos para tratar enfermedad de gaucher. - Google Patents

Composiciones y metodos para tratar enfermedad de gaucher.

Info

Publication number
MX344786B
MX344786B MX2015000528A MX2015000528A MX344786B MX 344786 B MX344786 B MX 344786B MX 2015000528 A MX2015000528 A MX 2015000528A MX 2015000528 A MX2015000528 A MX 2015000528A MX 344786 B MX344786 B MX 344786B
Authority
MX
Mexico
Prior art keywords
compositions
methods
gaucher disease
treating gaucher
treating
Prior art date
Application number
MX2015000528A
Other languages
English (en)
Inventor
W Heartlein Michael
F Daniel Peter
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX344786B publication Critical patent/MX344786B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2442—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende velaglucerasa, un lioprotector, una sal amortiguadora, y un agente de estabilización para usarse en el tratamiento de la enfermedad de Gaucher.
MX2015000528A 2009-07-28 2010-07-28 Composiciones y metodos para tratar enfermedad de gaucher. MX344786B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22919509P 2009-07-28 2009-07-28
US30304410P 2010-02-10 2010-02-10
US31751310P 2010-03-25 2010-03-25
US33337210P 2010-05-11 2010-05-11
US35933810P 2010-06-28 2010-06-28
PCT/US2010/043586 WO2011017177A1 (en) 2009-07-28 2010-07-28 Compositions and methods for treating gaucher disease

Publications (1)

Publication Number Publication Date
MX344786B true MX344786B (es) 2017-01-06

Family

ID=43527246

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001268A MX2012001268A (es) 2009-07-28 2010-07-28 Composiciones y metodos para tratar enfermedad de gaucher.
MX2015000528A MX344786B (es) 2009-07-28 2010-07-28 Composiciones y metodos para tratar enfermedad de gaucher.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012001268A MX2012001268A (es) 2009-07-28 2010-07-28 Composiciones y metodos para tratar enfermedad de gaucher.

Country Status (16)

Country Link
US (2) US20110027254A1 (es)
EP (2) EP3354277B1 (es)
JP (5) JP5815521B2 (es)
CN (3) CN102686237B (es)
AU (3) AU2010281403B2 (es)
CA (2) CA3120503A1 (es)
CO (1) CO6660423A2 (es)
ES (2) ES2668079T3 (es)
HK (2) HK1258919A1 (es)
IL (3) IL262668B1 (es)
MX (2) MX2012001268A (es)
NZ (3) NZ623910A (es)
PL (1) PL3354277T3 (es)
RU (2) RU2568831C2 (es)
WO (1) WO2011017177A1 (es)
ZA (2) ZA201200704B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7833766B2 (en) 2006-02-07 2010-11-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
EP2595651B1 (en) * 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
UA116194C2 (uk) 2011-10-28 2018-02-26 Протена Біосаєнсиз Лімітед Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
KR102086061B1 (ko) 2012-01-27 2020-03-11 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
MX361231B (es) * 2012-03-02 2018-11-30 Shire Human Genetic Therapies Composiciones y usos de las mismas para tratar la enfermedad de gaucher tipo iii.
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2961097C (en) 2014-09-15 2023-09-26 Orphazyme Aps Extended-release pharmaceutical formulation comprising arimoclomol
US20180296542A1 (en) * 2015-09-22 2018-10-18 Saint Louis University Iminosugars for improving bone mineral density in bone disease
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
CA3078463A1 (en) * 2017-10-26 2019-05-02 Shire Human Genetic Therapies, Inc. Formulations comprising glucocerebrosidase and isofagomine
AU2019276882A1 (en) * 2018-05-27 2021-01-14 Bioasis Technolgies Inc. Treatment of gaucher disease
US20230110129A1 (en) * 2019-04-25 2023-04-13 Takeda Pharmaceutical Company Limited Isofagomine salts, methods of use and formulations
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
RU2759054C2 (ru) * 2019-11-27 2021-11-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-Luc и способ оценки поствакцинальных нейтрализующих антител с использованием биолюминесцентной детекции
EP4139442A4 (en) * 2020-04-23 2024-06-19 Wuxi Biologics Ireland Limited GENETICALLY MODIFIED CELL LINE FOR THE PRODUCTION OF A RECOMBINANT GLYCOPROTEIN WITH A MANNOSE-TERMINATED N-GLYCAN
KR20230035586A (ko) * 2020-06-24 2023-03-14 켐팜 덴마크 에이/에스 고셔병을 치료하기 위한 아리모클로몰
JP2023544735A (ja) * 2020-10-01 2023-10-25 サンガモ セラピューティクス， インコーポレイテッド 抗ａａｖ抗体を検出する方法
NZ800483A (en) 2020-11-19 2024-03-22 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5241093B2 (es) 1973-05-16 1977-10-17
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
WO1989005850A1 (en) 1987-12-23 1989-06-29 The United States Of America, As Represented By Th Cloned dna for synthesizing unique glucocerebrosidase
DE68926569T2 (de) 1988-12-23 1996-09-26 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
JPH03503721A (ja) 1988-12-23 1991-08-22 ジェンザイム　コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
DE69213714T2 (de) 1991-01-21 1997-01-23 Genzyme Corp., Cambridge, Mass. Herstellung enzymatischer aktiver glukocerebrosidase von rekombinanten zellen
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
DK0675727T3 (da) 1992-12-10 2002-08-05 Enzon Inc Glycolipidenzympolymerkonjugater
WO1994014837A1 (en) 1992-12-21 1994-07-07 Enzon, Inc. Purification of proteinaceous material
JP3002113B2 (ja) 1994-03-30 2000-01-24 寳酒造株式会社 糖質又は複合糖質の製造方法
DE69521074T2 (de) 1994-03-30 2001-09-13 Takara Shuzo Co., Ltd. Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
WO1997010353A1 (en) 1995-09-14 1997-03-20 Virginia Tech Intellectual Property, Inc. Production of lysosomal enzymes in plant-based expression systems
WO1997032591A1 (en) 1996-03-05 1997-09-12 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6177447B1 (en) 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
NZ334721A (en) 1996-09-13 2001-01-26 Transkaryotic Therapies Inc Purified human alpha-galactosidase A and therapeutic use
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH10273500A (ja) 1997-03-03 1998-10-13 Noguchi Inst 複合糖ペプチド及びその製造法
JPH10306099A (ja) 1997-03-04 1998-11-17 Noguchi Inst 新規複合糖ペプチドおよびその製法
TW542721B (en) 1997-08-06 2003-07-21 Melaleuca Inc Dietary supplements containing natural ingredients
EP1003760B1 (en) 1997-08-07 2004-07-28 The University Of Utah Prodrugs and conjugates of selenium containing compounds and use thereof
US5939279A (en) * 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
GB9802249D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP0976838A1 (en) 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
JPH11318441A (ja) 1998-05-14 1999-11-24 Nagase & Co Ltd 超耐熱耐酸性アミロプルラナーゼ
KR19990086271A (ko) 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
AU4045599A (en) 1998-06-05 1999-12-30 Aventis Pharma S.A. Polypeptides with beta-secretase type activity
DE69942636D1 (de) 1998-12-09 2010-09-09 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
CA2378776A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
WO2001024814A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
WO2001049830A2 (en) 1999-12-30 2001-07-12 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
CN1156702C (zh) * 2001-07-11 2004-07-07 上海晶泰生物技术有限公司 采用标记链霉亲和素-生物素技术的蛋白质芯片
CA2468971A1 (en) 2001-12-04 2003-06-12 Mitsubishi Pharma Corporation Method of activating protein
PL213311B1 (pl) 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
US7429460B2 (en) * 2003-01-15 2008-09-30 Yeda Research And Development Co., Ltd. Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
EP2332567B1 (en) 2003-01-31 2015-04-08 The Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
KR20070012826A (ko) * 2004-04-16 2007-01-29 제넨테크, 인크. 항체에 대한 분석법
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
US7833766B2 (en) 2006-02-07 2010-11-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
ES2366059T3 (es) * 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
WO2007123984A2 (en) * 2006-04-18 2007-11-01 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions
WO2007140212A2 (en) 2006-05-24 2007-12-06 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
BRPI0713442A2 (pt) * 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
ES2440487T3 (es) * 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US20120328589A1 (en) 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
EP2595651B1 (en) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof

Also Published As

Publication number Publication date
IL259413B (en) 2018-12-31
AU2010281403B2 (en) 2016-03-10
AU2010281403A1 (en) 2012-03-01
ES2887552T3 (es) 2021-12-23
ES2668079T3 (es) 2018-05-16
IL262668B1 (en) 2024-06-01
CA3120503A1 (en) 2011-02-10
JP2015127333A (ja) 2015-07-09
JP6066503B2 (ja) 2017-01-25
CO6660423A2 (es) 2013-04-30
AU2016200739B2 (en) 2018-02-15
CN102686237A (zh) 2012-09-19
CN109172813A (zh) 2019-01-11
RU2733466C2 (ru) 2020-10-01
EP3354277A1 (en) 2018-08-01
RU2568831C2 (ru) 2015-11-20
ZA201200704B (en) 2018-11-28
US11571466B2 (en) 2023-02-07
HK1217449A1 (zh) 2017-01-13
IL262668A (en) 2018-12-31
CN105126086B (zh) 2019-05-14
US20110027254A1 (en) 2011-02-03
CA2768999A1 (en) 2011-02-10
ZA201505556B (en) 2017-03-26
WO2011017177A1 (en) 2011-02-10
JP2013500976A (ja) 2013-01-10
CN109172813B (zh) 2022-09-02
CA2768999C (en) 2021-07-20
JP5815521B2 (ja) 2015-11-17
NZ713967A (en) 2017-01-27
JP2016185980A (ja) 2016-10-27
EP2459212B1 (en) 2018-03-14
NZ598156A (en) 2014-06-27
CN102686237B (zh) 2018-10-19
AU2018203308A1 (en) 2018-05-31
RU2012107103A (ru) 2013-09-10
EP2459212A4 (en) 2013-04-24
CN105126086A (zh) 2015-12-09
EP3354277B1 (en) 2021-06-30
EP2459212A1 (en) 2012-06-06
AU2016200739A1 (en) 2016-02-25
JP6378257B2 (ja) 2018-08-22
RU2015141669A3 (es) 2019-04-23
AU2018203308B2 (en) 2020-04-23
RU2015141669A (ru) 2018-12-26
NZ623910A (en) 2016-06-24
IL217774B (en) 2018-12-31
HK1258919A1 (zh) 2019-11-22
MX2012001268A (es) 2012-09-12
JP2020033367A (ja) 2020-03-05
US20140242061A1 (en) 2014-08-28
JP2018077246A (ja) 2018-05-17
PL3354277T3 (pl) 2021-12-13
IL217774A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
IN2012DN02046A (es)
IN2012DN00548A (es)
IN2012DN00746A (es)
AP2012006064A0 (en) Compounds and methods for treating influenza.
IL218987A0 (en) Methods and compositions for treating cancer
BR112012003092A2 (pt) composições e métodos para implantação de tecido adiposo processado e produtos de tecido adiposo processados.
IN2012DN00568A (es)
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
ZA201203603B (en) Lyophilization methods, compositions, and kits
MX2011007930A (es) Conjugados de insulina cristalina.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EP2515794A4 (en) DENTAL COMPOSITIONS, GRINDING BLOCKS, AND ASSOCIATED METHODS
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
IL215932A0 (en) Compositions and methods for treating burns
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
EP2381920A4 (en) METHOD AND COMPOSITIONS FOR TREATING P.ACNES
IN2012DN03404A (es)
EP2438173A4 (en) BIOMATERIALS, COMPOSITIONS AND METHODS
WO2011057220A9 (en) Compositions and methods for treating lymphoma
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
EP2462131A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID
EP2393506A4 (en) METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES